FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Rep. Guthrie to Chair FDA Oversight Committee

[ Price : $8.95]

House leaders tap Representative Brett Guthrie (R-KY) to serve as chair of the House Energy and Commerce Committees Health Subcomm...

FDORA Requires Trial Diversity Action Plans: Attorneys

[ Price : $8.95]

Two Hyman, Phelps & McNamara attorneys describe requirements in the new Food and Drug Omnibus Reform Act to improve clinical trial...

New CBD Regulatory Framework Needed: Woodcock

[ Price : $8.95]

FDA principal deputy commissioner Janet Woodcock says the agency will work with Congress to develop a new cross-agency regulatory ...

Oncology Panel to Discuss Polivy sBLA for Lymphoma

[ Price : $8.95]

Federal Register notice: FDA announces a 3/9 Oncologic Drugs Advisory Committee meeting to discuss a supplemental BLA for Genentec...

Oncologist Debarred for Distributing Canadian Drugs

[ Price : $8.95]

Federal Register notice: FDA issues a three-year debarment order against Poornanand Palaparty for receiving and distributing presc...

Biological Therapies Need Clinical Trials: Califf, Marks

[ Price : $8.95]

FDA commissioner Robert Califf and CBER director Peter Marks explain why biological therapies should be tested in randomized contr...

Include all Media in Drug Promotion Regs: Professors

[ Price : $8.95]

Two professors call for updates to the FDA system for regulating drug promotion to account for new businesses that are promoting d...

CDRH OKd 19 Breakthrough Devices in 2022

[ Price : $8.95]

The CDRH 2022 annual report says the Center responded to many unique and important issues.

AstraZenecas Evusheld No Longer OK for Emergency Use

[ Price : $8.95]

FDA says AstraZenecas Evusheld is no longer authorized for emergency use to fight Covid-19 infections.

Emergent Recalls Skin Decontamination Lotion

[ Price : $8.95]

Emergent recalls certain Reactive Skin Decontamination Lotion kits from a specific batch based on customer complaints about leakag...